A Multi-Center, Open- Label, Single-Arm Phase 1 QT/QTc Study of SHR3680 in Subjects With Castration-Resistant Prostate Cancer
Latest Information Update: 17 May 2023
At a glance
- Drugs Rezvilutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 12 May 2023 Status changed from not yet recruiting to recruiting.
- 10 Nov 2022 New trial record